Radioiodine whole-body scans, thyroglobulin levels, 99mtc-mibi scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer

Nuclear Medicine Communications

Volumn 27, Issue 3, 2006, Pages 261-266

  Küçük, Özlem N ^a   Gültekin, Sinan S ^a   Aras, Gülseren ^a   İbiş, Erkan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Differentiated thyroid cancer; Iodine 131 whole body scan; Lung metastasis; Tg level

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; THYROGLOBULIN; TUMOR MARKER; IODINE 131; LEVOTHYROXINE;

ARTICLE; BLOOD; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICS; THYROID TUMOR; TURKEY (REPUBLIC); WHOLE BODY IMAGING; ADULT; AGED; BONE METASTASIS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATIONAL STUDY; DOSE RESPONSE; FOLLICULAR CARCINOMA; FOLLOW UP; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN TISSUE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PAPILLARY CARCINOMA; PHYSICAL EXAMINATION; RADIOGRAPHY; THYROID CANCER; TREATMENT DURATION; WHOLE BODY SCINTISCANNING;

COMORBIDITY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; TURKEY; WHOLE BODY IMAGING;

EID: 33646684043     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200603000-00009     Document Type: Article

References (19)

1. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gadret P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63:960-967.
2. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988; 67:501-508.
3. Hoie J, Stenwig AE, Kullmann G, Lindegard M. Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer 1988; 61:1-6.
4. Ronga G, Filesi M, Montesano T, Di Nicola AD, Pace C, Travascio L, et al. Lung metastases from differentiated thyroid carcinoma. Q J Nucl Med Moll Imaging 2004; 48:12-19.
5. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, Degroot L舁J. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79:98-105.
6. Nemec J, Nyvitova O, Blazek T, Vicek P, Racek P, Novak Z, et al. Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 1996; 23:69-71.
7. 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma. J Nucl Med 2000; 41:631-635.
8. Miyamoto S, Kasagi K, Misaki T, Alam MS, Konishi J. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med 1997; 38:352-356.
9. Mazzaferri EL, Massoll N. Management of papillary and follicular thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002; 9:227-247.
10. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87:1499-1501.
11. Morgenthaler NG, Froehlich J, Rendl J, Willnich M, Alonso C, Bergmann A, Reiners C. Technical evaluation of a new immunoradiometric and a new immunoluminometric assay for thyroglobulin. Clin Chem 2002; 48:1077-1083.
12. Filesi M, Signore A, Ventroni G, Melacrinis FF, Ronga G. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 1998; 39:1542-1546.
13. Sundram FX, Goh AS, Ang ES. Role of technetium-99m sestamibi in localization of thyroid cancer metastases. Ann Acad Med Singapore 1993; 22:557-559.
14. Dadparvar S, Chevres A, Tulchinsky M, Krishna-Badrinath L, Khan AS, Sizofski WJ. Clinical utility of technetium-99m methoxyisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 scintigraphy and serum thyroglobulin quantitation. Eur J Nucl Med 1995; 22:1330-1338.
15. Lorenzen J, Beese M, Mester J, Brumma K, Beyer W, Clausen M. Chest X ray: routine indication in the follow-up of differentiated thyroid cancer? Nuklearmedizin 1998; 37:208-212.
16. Piekarski JD, Schlumberger M, Leclere J, Couanet D, Masselot J, Parmantier C. Chest computed tomography in patients with micronodular lung metastases of differentiated thyroid carcinoma. Int J Radiat Oncol Biol Phys 1985; 11:1023-1027.
17. 18F-2-Fluoro-2-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic I-131 iodine whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84:2291-2302.
18. Shiga T, Tsukamoto E, Nakada K, Morita K, Morita K, Kato T, et al. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001; 42:414-419.
19. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Breennan MF, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003; 197:191-197.